A
AYOXXA
International biotech company focused on the development of its proprietary beads-on-a-chip technology for advanced protein analysis an biotech company commercializing innovative technology
About AYOXXA
AYOXXA Biosystems is a biotechnology company specializing in translational proteomics, focusing on multiplex protein analysis for biomarker quantification. The company serves leading scientists and researchers in the fields of ophthalmology, immune responses, and immuno-oncology. Operating within the life sciences market, AYOXXA's business model revolves around providing a scalable and integrated platform that includes proprietary technology, dedicated readers, and intuitive software for data analysis. This platform allows for the quantification of up to 12 biomarkers in minimal sample volumes, offering transparent assay outcomes and superior data quality. AYOXXA generates revenue through the sale of its multiplex protein analysis systems and associated consumables, as well as through research collaborations and partnerships. The company’s technology is validated for various biofluids, tissue samples, and cell cultures, making it versatile for both basic research and clinical applications.
Source: Dealroom company dataAt a glance
- Founded
- 2010
- Headquarters
- Cologne, Germany
- Sector
- Biotech & Life Sciences
Knowledge graph
More headlines
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A8 investors entered at this stage
Series B and later1 investor entered at this stage
- PCProsnav Capital
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about AYOXXA on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See AYOXXA on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.







